Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

The final presentation, a poster entitled Brilacidin, Host Defense Peptide Mimetic, One of a New Class of Immunomodulatory Agents that can Target Multiple Disease Indications, will be given in the category of New Antimicrobials. “This is an important poster, as it highlights the immunomodulatory properties of Brilacidin, in addition to its antimicrobial properties,” Dr. Jorgensen added. “These animal data support the use of topical Brilacidin in humans to prevent or ameliorate oral mucositis, a painful condition in cancer patients undergoing chemoradiation therapy. A phase 2 clinical trial is about to begin.” - See more at: http://cellceutix.com/cellceutix-phase-2b-clinical-trial-of-brilacidin-accepted-for-oral-presentation-at-the-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid/#sthash.gYBYcCYv.dpuf


Here's the other poster TOB. We should be able to view abstracts on Wednesday. Possibly news before then?


Title Brilacidin, host defence peptide mimetic, one of a new class of immunomodulatory agents that can target multiple disease indications

Poster No: EV0201
Author(s): Scott Richard W., Sonis Stephen T., Kroczak Bozena, Freeman Katie B., DeGrado William F, Holden Sylvia A., Kumar Ashok, Chafai-Fadela Karima, Ram Siya, Menon Krishna
Affiliation(s): Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, NewMed, Wayne PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, University of California, San Francisco CA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA
Session: EV06 Antimicrobials: new antimicrobials
Date: Saturday - April 25, 2015 00:00
Location: ePoster Area
Subtopic: Antimicrobials: new antimicrobials
Topic: ePoster Viewing


Abstracts will be visible starting 15 April 2015



http://eccmid.meetingexpert.net/ECCMID_546/poster_124310/program.aspx


in reply to TOB

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx